Three CardioCell-Sponsored Studies Reveal Results at the European Society of Cardiology (ESC) Congress 2016

"Hot Line" Late-Breaking Session Unveils Phase IIa Clinical Trial Results, While a Poster Session and a "Stem Cells & Cell Therapy" Session Share Pre-Clinical Study Data From the Application of CardioCell's Stem Cells for Cardiovascular Indications

News provided by

CardioCell LLC

16 Aug, 2016, 09:15 ET

ROME, Italy, Aug. 16, 2016 /PRNewswire/ -- EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2016 – CardioCell LLC, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, announces results from three of its sponsored studies are accepted for presentation at ESC Congress. Each study – a Phase IIa clinical trial and two pre-clinical studies – applies CardioCell's unique ischemia-tolerant mesenchymal stem cells (itMSCs) for cardiovascular indications. Visit the presentations as follows:

"Hot Line" Late-Breaking Session:

"Safety and efficacy of intravenous infusion of ischemia tolerant allogeneic mesenchymal stem cells in patients with non-ischemic cardiomyopathy"

When:

Sunday, Aug. 28, 2016, from 12:12 to 12:22 p.m. CET

Where:

Main Auditorium, Fiera di Roma

Presenter:

Paper Co-Author Dr. Javed Butler, Chief of the Cardiology Division at Stony Brook University, Co-chair of CardioCell's Heart Failure Advisory Board and Member of CardioCell's Scientific Advisory Board


Poster Session 3:

"Mesenchymal stem cells grown under chronic hypoxia improve LV function and inhibit adverse remodeling in mice with chronic ischemic cardiomyopathy"

When:

Sunday, Aug. 28, 2016, from 2-6 p.m. CET

Where:

Poster Area, Fiera di Roma

Presenter:

Paper Co-Author Dr. Michael Lipinski, ‎Interventional Cardiologist at MedStar Washington Hospital Center


"Stem Cells & Cell Therapy" Session:

"Mesenchymal stem cells grown under chronic hypoxia traffic to regions of myocardial infarction, suppress splenic natural killer cells, and attenuate adverse remodeling in mice with large acute MI"

When:

Monday, Aug. 29, 2016, from 5:51-6 p.m. CET

Where:

Agora 2 – Poster Area, Fiera di Roma

Presenter:

Paper Co-Author Dr. Michael Lipinski, ‎Interventional Cardiologist at MedStar Washington Hospital Center

About CardioCell LLC
Founded in San Diego, California, in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company's technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the United States, Europe and the former Soviet Union. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction, chronic heart failure and peripheral artery disease. For more information, visit www.stemcardiocell.com.

About Stemedica Cell Technologies Inc.
Stemedica Cell Technologies Inc. is a global biopharmaceutical company that manufactures best-in-class allogeneic adult stem cells and stem cell factors. The company is a government licensed manufacturer of cGMP, clinical-grade stem cells currently used in US-based clinical trials for acute myocardial infarction, chronic heart failure, cutaneous photoaging, ischemic stroke, Alzheimer's disease and traumatic brain injury. Stemedica's products are also used on a worldwide basis by research institutions and hospitals for pre-clinical and clinical (human) trials. Stemedica is currently developing additional clinical trials for other medical indications using adult, allogeneic stems cell under the auspices of the FDA and other international regulatory institutions. The company is headquartered in San Diego, California, and can be found online at www.stemedica.com.

All media inquiries: 
Kimberly Stoddard
The Townsend Team
+1 415.806.5793
[email protected]

Logo - http://photos.prnewswire.com/prnh/20150309/180568LOGO

SOURCE CardioCell LLC

Related Links

http://stemcardiocell.com

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.